Onco-Innovations Ltd.
ONCO.CN
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.19M
Close$
Share Statistics
| Market cap | $28.19 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $-0.01 |
| Beta | 8.62 |
| Outstanding Shares | 57,548,408 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Onco-Innovations Limited
CEO: Thomas O'Shaughnessy Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company's lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3'-P...